Sign in

    ANI PHARMACEUTICALS (ANIP)

    Q2 2025 Earnings Summary

    Reported on Jan 1, 1970 (Before Market Open)
    Pre-Earnings Price$69.01Last close (Aug 7, 2025)
    Post-Earnings Price$77.86Open (Aug 8, 2025)
    Price Change
    $8.85(+12.82%)
    MetricYoY ChangeReason

    Overall Revenue (Q1 2024)

    29% YoY increase

    This growth was driven by strong performance across segments including a 126% jump in Rare Disease, 10% growth in Generics, and a 13% uptick in Established Brands, reflecting expanded market reach and operational efficiency.

    Rare Disease Segment – Purified Cortrophin Gel (Q1 2024)

    126% YoY increase

    The surge was due to increased prescription volumes, expansion into new specialties such as pulmonology and ophthalmology, and the product innovation with a new 1 mL vial size targeting acute conditions.

    Generics Segment (Q1 2024)

    10% YoY increase

    Growth in the generics segment was driven by increased base volumes and the successful launch of new products, including a Competitive Generic Therapy with 180-day exclusivity.

    Established Brands (Q1 2024)

    13% YoY increase

    The increase in this segment was supported by higher sales volumes and favorable supply chain tailwinds, contributing positively to overall revenue.

    Generics Segment (Q1 2025)

    40.5% YoY increase to $98.7 million

    This robust growth was fueled by markedly increased volumes and successful new product launches, such as the market-first prucalopride tablets with 180-day exclusivity, outperforming prior period performance in this segment.

    Rare Disease – Cortrophin Gel (Q1 2025)

    43.1% YoY increase to $52.9 million

    Growth in this metric was driven by a record number of new patient starts and sustained high prescription volumes, signaling continued strength compared to the previous period's performance despite a moderated rate.

    Rare Disease Overall (Q1 2025)

    86.7% YoY increase to $69.0 million

    This overall increase reflects both strong organic growth and strategic impacts such as the Q3 2024 Alimera acquisition, which contributed $16.1 million in revenues, further consolidating gains from previous periods.

    Brands Portfolio (Q1 2025)

    –2.2% YoY decrease to $25.1 million

    The slight decline suggests potential market saturation or a strategic shift in focus, possibly as resources were reallocated towards the higher-growth Generics and Rare Disease segments, contrasting with the strong growth observed in earlier periods.

    Research analysts covering ANI PHARMACEUTICALS.